India's pharmaceutical exports to Bulgaria are predominantly in the therapeutic areas of oncology, cardiovascular diseases, and urology. These categories align with Bulgaria's significant healthcare needs, particularly in managing chronic conditions and complex diseases.
Oncology drugs, such as abiraterone acetate, are crucial due to the rising incidence of cancer in Bulgaria. The country's pharmaceutical market is witnessing a surge in demand for affordable generic medicines, with oncology drugs being a leading segment.
Cardiovascular medications, including olmesartan, address the high prevalence of hypertension and related cardiovascular conditions among the Bulgarian population. The National Health Insurance Fund's budget for medicines, medical devices, and dietary foods in 2023 was set at around USD 946 million, a 16.75% increase from the prior year, indicating strong public spending growth on pharmaceuticals.
Urology drugs, such as tamsulosin hydrochloride, cater to the aging population's needs, as older adults are more susceptible to urological disorders. The high out-of-pocket payments for healthcare in Bulgaria, accounting for 34% of total health expenditure, underscore the demand for cost-effective treatments in these therapeutic areas. (eurohealthobservatory.who.int)
